Dr Goelet is a scientist, entrepreneur and investor with management experience in biotechnology and venture capital funding. He received his Ph.D. in biochemistry from the University of Cambridge, studying with Drs. Sydney Brenner and Jonathan Karn at the Laboratory of Molecular Biology.
He then worked as a Helen Hay Whitney Fellow between 1984 and 1987 at Columbia University in the laboratory of Dr. Eric Kandel. In 1990 he founded Molecular Tool, Inc., where he co-invented SNP (“single nucleotide polymorphismâ€) analysis technology. As its CEO, he completed Molecular Tool’s merger with GeneScreen, and subsequently as a Director of GeneScreen he participated in its acquisition in 1999 by Orchid Biosciences, Inc. (NASDAQ: ORCH), where he served on the Scientific Advisory Board. Between 1995 and 2001, he served as an officer and director of the Rhode Island Corporation (a private investment company) and its successor, NORIC, which was acquired by Pogo Producing Company (NASDAQ: PPP) in 2001.
In 1997, he participated in the formation of RiboTargets, Plc., UK (an RNA structure-based drug discovery company), on whose board he served until 2000. Currently, he is a director of Red Abbey Venture Partners, LLC, a life sciences private equity partnership, formed with Frank Bonsal and Matt Zuga.
